Vaxart Reports Q1 2025 Progress and Financials

Vaxart ( (VXRT) ) has released its Q1 earnings. Here is a breakdown of the information Vaxart presented to its investors.

Vaxart, Inc. is a clinical-stage biotechnology company specializing in the development of oral recombinant vaccines using a proprietary delivery platform, aiming to provide needle-free vaccination solutions for various viral diseases.

In its first quarter of 2025, Vaxart announced significant progress in its vaccine development programs, including the COVID-19 and norovirus vaccines, alongside promising results from its avian influenza vaccine candidate. The company also reported a financial update, highlighting increased revenue and a reduced net loss compared to the previous year.

Key financial metrics from the first quarter of 2025 include a revenue increase to $20.9 million, primarily from government contracts, and a net loss reduction to $15.6 million. The company is actively managing its cash runway, which currently extends into 2026, and exploring strategic partnerships to support its ongoing clinical and regulatory milestones. Additionally, Vaxart has appointed Jeroen Grasman as the new Chief Financial Officer, effective May 19, 2025.

Looking ahead, Vaxart remains focused on advancing its vaccine candidates through clinical trials, with plans to begin dosing for the COVID-19 Phase 2b trial in the second quarter of 2025 and to report topline data for the norovirus vaccine in mid-2025. The company continues to prioritize cost management and strategic partnerships to achieve its long-term objectives.